

# Special Symposium

## New Frontiers in Neurodegeneration

May 18-19, 2011

Biogen Idec

15 Cambridge Center (Building 8)  
Cambridge, MA

### Speakers and Topics:

Robert Brown (UMass Med)	The emerging genetic landscape of ALS
Steven Finkbeiner (UCSF/Gladstone Inst)	Defining neurodegenerative pathways
Li-Huei Tsai (MIT/Picower)	AD, ALS and Aging
Aaron Gitler (UPenn)	Studying protein misfolding diseases in yeast
Eran Hornstein (Weizmann Inst)	MicroRNA malfunction and motor neuron disease
Anthony Antonellis (UMich Med)	tRNAs and neuronal viability
Susan Ackerman (Jackson Labs/HHMI)	Mouse models of neurodegeneration
Timothy Miller (Wash U)	Approaches for gene silencing in ALS therapy
Christopher Henderson (Columbia)	New insights into MN susceptibility in ALS
Kevin Eggan (Harvard/HHMI)	Motor neuron-glia interactions and stem cells
Marc Freeman (UMass Med/HHMI)	Molecular pathways mediating axon death
Michael Coleman (U Cambridge)	Axon degeneration and disease
David Rubinsztein (U Cambridge)	Autophagy and neurological disease
Myriam Heiman (MIT/Picower)	TRAPping Huntington's and Parkinson's diseases
Ed Boyden (MIT Media Lab)	Optogenetic manipulation of neuronal circuits
Dwight Bergles (Johns Hopkins U)	NG2+ stem cells in development and disease

Attendance limited to 200 participants.  
Email [NTI@umassmed.edu](mailto:NTI@umassmed.edu) to register.

Organized by the UMMS Neurotherapeutics Institute (UMASS NTI)  
Sponsored by Biogen Idec and the ALS Therapy Alliance (ATA)



UMASS  
NTI

biogen idec

ALS  
THERAPY ALLIANCE